Delving into the Latest Updates on Genmedica Therapeutics SL with Synapse

Overview

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of multiple oral doses of GMC-252-L-Lysine salt (GMC-252) in healthy subjects and type 2 diabetics.
The secondary objective is to explore the effect of multiple oral doses of GMC-252 on pharmacodynamic(PD) parameters in type 2 diabetics.

Start Date01 Apr 2016

Sponsor / Collaborator

Genmedica Therapeutics SL

[+1]

NCT02686281

/ TerminatedPhase 1

A Double-Blind, Placebo-Controlled, Randomised, Two Part Study of the Safety and Pharmacokinetics of GMC-252 in A) Healthy Male Subjects, Including a Comparison of GMC-252 Dosing in the Fed and Fasted States ,and B) in Subjects With Type 2 Diabetes Mellitus

The purpose of this study is to determine the toxicity, tolerability and safety of single ascending doses of GMC-252-L-Lysine Salt in healthy male subjects.

Start Date01 Sep 2012

Sponsor / Collaborator

Genmedica Therapeutics SL

[+1]

100 Clinical Results associated with Genmedica Therapeutics SL

Login to view more data

0 Patents (Medical) associated with Genmedica Therapeutics SL

Login to view more data

100 Deals associated with Genmedica Therapeutics SL

Login to view more data

100 Translational Medicine associated with Genmedica Therapeutics SL

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 11 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

2

Login to view more data